Toxoplasma gondii is a ubiquitous parasite, which causes several serious diseases. Until the AIDS pandemic, toxoplasmic encephalitis was largely confined to the pharmacologically immunesuppressed and to cases of congenital transmission. T gondii is now one of the more commonly encountered opportunistic pathogens of advanced AIDS. 
Pathogenesis
Tgondii spreads by invading and disrupting contiguous cells, and by dissemination in nucleated blood cells. Tachyzoites proliferate, causing local necrosis and stimulating a mononuclear cell reaction. Even so, in immunocompetent people, acute toxoplasmosis may go unnoticed -it is symptomatic in only 20% of cases.
Eventually, such acute infection becomes controlled by host defences including non-specific cellular mechanisms (including macrophages and natural killer cells), specific cellular immunity (cytokines, including y-interferon, seem to have a major role) and humoral immunity (IgG, IgM, IgA and IgE).
Tachyzoites have the ability to 'transform' into bradyzoites, which are contained within tissue cysts. This parasite stage is able to elude host defences, and may remain viable for many years as an asymptomatic latent infection. Cysts can be found in any tissue, but are common in brain, striated muscle and the heart. From time to time, bradyzoites may 'escape' from cysts, without disruption of the cyst wall. In the immune-competent host this 'leakage' may give rise to 'daughter cysts'. In immuno-suppressed patients, however, such escape may give rise to re-activation of the latent infection.
The commonest site for re-activation is the central nervous system (CNS), although disease may occur elsewhere, such as the lungs. It is unclear whether CNS disease results from disruption of tissue cysts locally, or whether there is haematogenous spread of tachyzoites from other sites. The CNS lesions comprise patchy meningoencephalitis and necrosis (often due to vascular involvement), and these result in the clinical syndrome known as toxoplasmic encephalitis (figure 1). Use of cotrimoxazole, as prophylaxis against P carinii pneumonia, may confer benefit as may the combination of pyrimethamine with dapsone. However, the use of prophylactic pyrimethamine in addition to cotrimoxazole may increase death rate -a reminder that these drugs are far from innocuous.
Drugs used for treatment and maintenance PYRIMETHAMINE Mode of action (figure 2) The conversion of 2'deoxyribosyluracil monophosphate to 2'deoxyribosylthymine monophosphate is essential for normal DNA synthesis in mammals and protozoa; this is accomplished by donation of a methyl group by methylenetetrahydrofolate and the process is catalysed by thymidylate synthetase. The oxidised product, dihydrofolate, must be reduced back to replenish the 'pool' of methylene tetrahydrofolate: the rate-limiting step of this process is catalysed by dihydrofolate reductase, and pyrimethamine competes with dihydrofolate for this enzyme. Pyrimethamine is active against tachyzoites, but ineffective against tissue cysts; it is unknown whether this is due to failure ofpyrimethamine to cross the cyst wall, or because of differences between bradyzoites and tachyzoites.
Pharmacokinetics (box 4)
Pyrimethamine4 is available only as tablets, although Fansidar®) (pyrimethamine plus sulfadoxine; Roche) does have an intramuscular formulation. Pyrimethamine is rapidly and extensively absorbed when given orally to patients with malaria, but absorption from intramuscular Fansidar is slower. 5 The extent and rate of absorption of oral pyrimethamine by AIDS sufferers with toxoplasmic encephalitis seems to be highly variable.6 Pyrimethamine is widely distributed to the tissues, and concentrates in brain tissue. 15) is converted to the triazine WR99210 -one of the most potent antimalarial drugs known. Combination of WR250417 with either a sulphonamide or a sulphone seem to be efficacious against both T gondii and P carinii.
The methotrexate analogues, trimetrexate and piritrexim, are effective against Tgondii infections, and have been used clinically. However, both are limited by haematological toxicity.
SULFADIAZINE AND OTHER SULPHONAMIDES
Mode of action (figure 2) Sulphonamides inhibit the incorporation of para-aminobenzoic acid into dihydropteroate, a precursor of dihydrofolate, by competitively inhibiting the enzyme dihydropteroate synthetase which is an enzyme of many micro-organisms (including bacteria and Plasmodia) but is not possessed by mammals. Against T gondii sulfadiazine is synergistic with pyrimethamine at lower concentration than other sulphonamides, and is therefore preferred. Other sulphonamides with reasonable activity against T gondii include sulphamethoxazole and sulphadimidine; in contrast, sulfadoxine has very low potency.
Pharmacokinetics (box 6)
The disposition of sulfadiazine in patients with advanced HIV-disease has not been thoroughly studied. In healthy subjects sulfadiazine seems to be rapidly absorbed from the gut, mainly from the small intestine: peak plasma levels are achieved within four hours of oral dosing. An intravenous formulation is available for use in patients with impaired consciousness. Sulfadiazine is widely distributed throughout the body: concentrations in brain tissue have not been measured, but those in the cerebrospinal fluid (CSF) are about 70°/O those in the plasma. Sulfadiazine is eliminated mainly by acetylation; the rate of this process is genetically determined, individuals being classed as rapid or slow acetylators. Both sulfadiazine and (inactive) metabolite are excreted in the urine, but much sulfadiazine is reabsorbed by the tubules; sulfadiazine clearance is increased in the presence of alkaline urine, and decreased in renal failure. The elimination half-time of sulfadiazine is 6-12 h in those with normal renal and hepatic function. Pyrimethamine/clindamycin seems to be about as effective as pyrimethamine/ sulfadiazine,4 though data are incomplete.
Adverse effects In the dosages used (1.2 g six hourly intravenously for up to three weeks, followed by 300 mg six hourly by mouth thereafter) toxicity from clindamycin is common (box 8); quinidine-like cardiotoxicity is a special problem if the drug is given rapidly intravenously.
Other macrolides and lincosamines Of the newer macrolides, azithromycin is probably the most potent, and also seems to have activity against bradyzoites in tissue cysts: its role is still being studied.
ATOVAQUONE
Because of the poor risk: benefit ratios of existing drugs, and the increasing frequency of toxoplasmic encephalitis in late AIDS, new chemotherapeutic agents are under investigation. Perhaps the most promising is atovaquone, an hydroxynaphthoquinone inhibitor of mitochondrial ubiquinones. Atovaquone was developed as an antimalarial drug, but also has potent antitoxoplasma activity against both tachyzoites and bradyzoites. Atovaquone synergises with sulphonamides and pyrimethamine. Although atovaquone is not yet generally available, the manufacturer will often provide it on a 'named-patient basis'.
